RCID: 744958
Link to this profile: http://www.researchcrossroads.org/Researchers/744958
Martin Edelman
UNIVERSITY OF MARYLAND, GREENEBAUM CANCER CENTER| Position Professor Of Medicine Department Medicine Website Degrees B.S., Biology (cum laude), Rensselaer Polytechnic Institute M.D., The Albany Medical College Postdoctoral Scholar, University of California, Interests Lung Cancer, Oncologic Phase I Drug Development. All Funding $ 913,909 |  |
Grants (Principal Investigator)
Grants for which Martin Edelman acted as the principal investigator
| Title/Granting Organization | Fiscal Years | Total Funding | |
|---|---|---|---|
| Telemere Targeted Therapy In Lung Cancer | |||
| National Cancer Institute(NCI) | 2009 | $ 226,209 | |
| Cancer And Leukemia Group B | |||
| National Cancer Institute(NCI) | 1998 - 2002 | $ 317,028 | |
| Phase I Trials Of Anticancer Agents | |||
| National Cancer Institute(NCI) | 1998 | $ 370,672 | |
Publications
| Edelman MJ, Gandara DR. Small cell lung cancer current status of new chemotherapeutic agents. Critical Reviews in Oncology/Hematology 27:211-220, 1998.
Edelman MJ, Meyers FJ, Grennan T. Phase II trial of pyrazine-2-diazyhydroxide in hormone refractory prostate cancer. Investigational New Drugs 16:179-182, 1998. Lara PN, Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol 42:504-508, 1998. Mack PC, Gandara DR, Bowen C, Edelman MJ, Panglieroni T, Schnier JB, Gelman EP, Gumerlock PH. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clinical Cancer Research 5:2596-2604, 1999. Edelman MJ, Gandara DR. Sequential chemotherapy: rationale and clinical trial design in advanced non-small cell carcinoma. Clinical Lung Cancer 1:122-127, 1999. Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O’Mahony M, Uhrich M, Lauder I, Houston J, Gietzen DW. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 86:684-688, 1999. Edelman MJ, Meyers FJ, Miller TR, Williams SG, Gandour-Edwards R, deVere White RW. Phase I/II trial of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well tolerated regimen with activity independent of p53 mutation. Urology 55:521-525, 2000. Edelman MJ, Quam H, Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small cell lung cancer cell lines. Cancer Chemo Pharm 48:141-144, 2001. Edelman MJ, Gandara DR, Lau D, Lara P, Lauder J, Tracy D. Sequential combination chemotherapy in advanced non-small cell lung cancer: carboplatin and gemcitabine followed by paclitaxel. Cancer 92:146-152, 2001. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DHM, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. Activity of high dose torimefene plus cisplatin in previously platinum-treated non-small cell lung cancer: A Phase II California consortium trial. Cancer Chemo and Pharm 48:22-28, 2001. Edelman MJ, Suntharalingam M, Krasna MJ. Management of patients undergoing multimodality therapy for non-small cell lung cancer. Current Treatment Options in Oncology 4:45-53, 2003 Edelman MJ, Gandara DR, Israel V, De Santo J, Hausner P, Doyle LA. Cryptophycin 52 in the treatment of platinum resistant non-small cell lung cancer. Lung Cancer 39:197-199, 2003. Edelman MJ, Bauer K, Khanwani S, Van Echo D, Karp J. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemotherapy and Pharm 51:439-444, 2003. Perez EA, Gandara DR, Edelman MJ, O’Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other malignancies. Cancer Investigation 21:1-6, 2003. Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology 51:337-348, 2003. Edelman MJ, Suntharalingam M, Krasna MJ. Management of patients undergoing multimodality therapy for non-small cell lung cancer. Current Treatment Options in Oncology 4:45-53, 2003 Edelman MJ, Gandara DR, Israel V, De Santo J, Hausner P, Doyle LA. Cryptophycin 52 in the treatment of platinum resistant non-small cell lung cancer. Lung Cancer 39:197-199, 2003. Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology 51:337-348, 2003. Abdel-Aziz W, Hickey RJ, Edelman M, Malkas LH. Effect of novel benzoylphenylurea derivatives on DNA polymerase alpha activity using the DNA synthesome model in vitro model system. Invest New Drugs 21:421-428, 2003. Edelman MJ, Chansky K, Crowley J, Leigh B, Gaspar L, Livingston R, Gandara D. Phase II (SWOG 9713) trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small cell lung cancer. J Clin Oncol 22:127-132, 2004. Lara PN Jr, Meyers FJ, Law LY, Dawson NA, Houston J, Lauder I, Edelman MJ. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer 100: 82-88, 2004. Edelman MJ, Clark J, Chansky K, Albain K, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022-5026, 2004. Patel AB, MD, Suntharalingam M, Kwok Y, Krasna MJ, Edelman MJ. Predictors of radiation esophagitis in patients with non-small cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiation therapy followed by surgery. Int J Rad Biol and Therapy 60:1106-1112, 2004. Edelman MJ, Smith R, Kendall J, Doyle LA, Hausner P, Kalra K, Bedor M, Bisaccia S. Phase II trial of the novel retinoid, bexarotene, and gemcitabine/carboplatin in advanced non-small cell lung cancer 2005, 23:5774-8. J Clin Oncol Edelman MJ. The role of bortezomib in chemoradiotherapy of non-small cell lung cancer. Clin Lung Ca 2005, 7 suppl 2: S64-S66. Bellil Y and Edelman MJ. Bronchogenic carcinoma in solid organ transplant recipients. Current Treatment Options in Oncology. 2006, 7:77-81. Edelman MJ. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer, Sem Oncol 32 (suppl 10):S3-S8, 2006. Edelman MJ, Sekine I, Tamura T, Saijo N. Geographic Variation in the Second Line Treatment of Non-small-Cell Lung Cancer. Sem Oncol (in press, 2006) Hamilton J, Krasna M, Doyle A, Edelman MJ, Suntharalingam M, Meltzer S. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. J Clin Gastroenterology and Hepatology. (in press, 2006) Ritch P, Rudin CM, Bitran JD, Edelman MJ, Makalinao A, Irwin D, Lillenbaum R, Peterson P, John WJ. Phase II Study of PKC-alpha Antisense Oligonucleotide Aprinocarsen in Combination With Gemcitabine and Carboplatin in Patients With Advanced Non-small Cell Lung Cancer Lung Cancer. 2006 Feb 25; [Epub ahead of print] |
Patents
Search USPTO for Martin Edelman Patents